Dumitrita Urescu

Dumitrita Urescu

Auto-generated profile, based on publicly available information

Dumitrita Urescu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in The Moldovan Medical Journal
Verified
Journal Article
Closed access
VTVictor Tomacinschii
Victor Tomacinschii
MRMaria Robu
Maria Robu
BSBuruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
Buruiana Grants access to events, meetings, and networking opportunities that help individuals raise their pr Sanda
VFVeronica Finciuc
Veronica Finciuc
AGAna Grecu
Ana Grecu
MSMarina Suschevici
Marina Suschevici
Background: Non-Hodgkin’s lymphomas (NHL) are malignant tumors that develop from lymphoid tissue. Primary lymph node (LN) involvement is the most common localization (52-70%). The integration of Rituximab (R) in the NHL treatment represented a turning point. The aim of this study was to evaluate the therapeutic impact of the use of R in combination with conventional polychemotherapeutic (PChT) in the treatment of nodal onset NHL. Material and methods: A descriptive cohort study was performed on 80 patients diagnosed with NHL. Results: In the study participated: men – 39(48.8%), women – 41(51.2%). The mean age of the patients was 56.09 ± 13.6 years. The onset of NHL occurred in peripheral l/n in 85.0% of cases, in mediastinal LN – 7.5%, and abdominals in 7.5%. Stages I-II were identified in 21(26.2%) patients, stages III-IV in 59(73.8%) cases. Aggressive NHLs were diagnosed in 54(67.5%) patients, indolent NHLs in 26(32.5%) cases. In 61(76.3%) patients, first-line R+PChT treatment was applied – group 1(G1), and in 19(23.8%) cases conventional PChT was applied – group 2(G2). The overall response rate (ORR) in G1 was 86.8%, in G2 – 63.1%. Complete remissions (CR) were obtained in G1 in 63.9% of patients, in G2 – 47.3% of cases. Progression-free survival (PFS) in G1 had a median of 20 months, and in G2 the median was 12 months (p <0.05). Conclusions: The use of Rituximab increased the ORR rate (86.8% vs 63.1%), the frequency of CR (63.9% vs 47.3%) and PFS (20 months vs 12 months (p <0.05).

28 December 2025 in Documenta Haematologica - Revista Romana de Hematologie
Verified
Journal Article
Closed access
DUDumitrita Urescu
Dumitrita Urescu
VMVasile Musteata
Vasile Musteata
MRMaria Robu
Maria Robu
AGAliona Golub
Aliona Golub
Primary bone lymphoma (PBL) is a neoplasm of malignant lymphoid cells that presents with one or more bone lesions without nodal or extranodal involvement. It accounts for approximately 7% of primary malignant bone tumors and can occur at any age, although it is most frequently diagnosed between 45 and 60 years, with a slight male predominance. The etiology of PBL remains unclear; however, several factors have been implicated in its development, including hereditary exostoses, AIDS, sarcoidosis, trauma, and bacterial or viral infections. The predominant histological subtype is diffuse large B-cell lymphoma. Most patients are diagnosed at stage IV, as the clinical presentation of PBL is generally nonspecific, often leading to delayed diagnosis. The most common symptom is localized bone pain in the affected area. Diagnosis requires a combination of histopathological and immunohistochemical examination. The treatment of PBL is based on systemic therapy, with current approaches including chemotherapy or immunochemotherapy with or without radiotherapy. Overall, PBL carries a generally favorable prognosis.

1 March 2026 in Moldovan Journal of Health Sciences
Verified
Journal Article
Open access
LMLarisa Musteata
Larisa Musteata
MRMaria Robu
Maria Robu
VMVasile Musteata
Vasile Musteata
DUDumitrita Urescu
Dumitrita Urescu
ICIrina Cebanu
Irina Cebanu
ACAlina Capanji
Alina Capanji
Introduction. The gastrointestinal tract (GIT) is the most common site of extranodal primary non-Hodgkin lymphoma (NHL), accounting for 20% to 40% of all extranodal lymphomas. The advanced stages at diagnosis and complications remain significant issues in NHL management, imposing a substantial disease burden on patients and healthcare systems. Material and methods. We performed a descriptive cross-sectional and cohort study of patients with gastrointestinal NHL and a narrative review of the literature in the Discussion section. This study included 50 prospective and retrospective patients with NHL treated between 2015-2024 in the Institute of Oncology in Moldova. A bibliographic search was conducted using databases such as PubMed, Hinari, SpringerLink, the National Center for Biotechnology Information, and Medline. The final bibliography included 18 relevant sources deemed to be representative of the literature published on the topic of this article. Results. According to the International Clinical Classification, most patients (22, 44.0%) were diagnosed with clinical stage IV. B symptoms occurred in 38 (76.0%) patients. The overwhelming predominance of diffuse large B-cell lymphomas (46 cases - 90.2%) was observed. The complete blood count, bone marrow aspiration and biopsy of the iliac crest did not detect any specific changes in cases without bone marrow involvement, with the exception of a decrease in hemoglobin and erythrocyte counts observed in cases of posthemorrhagic anemia. The overall survival (OS) of all patients with gastrointestinal NHL was 78.1% at 1 year, 59.4% at 3 years, and 35.9% at 5 years. In patients with stage IE NHL, the 1-, 3-, and ≥5-year OS was 93.4%, 76.5%, and 69.9%, respectively. In patients with stage IIE, the OS was 91.2% at 1 year, 71.4% at 3 years, and 63.8% at ≥5 years. In patients with stage IIIE-IV, the OS was 75.1% at 1 year, 54.8% at 3 years, and 28.5% at ≥5 years with combined chemotherapy. Conclusions. Our study demonstrated that non-Hodgkin lymphomas with primary involvement of the gastrointestinal tract exhibited distinct histopathological, clinical-evolutionary and hematological features, which influenced treatment outcomes. The aggressive histological types and the advanced stages IIIE and IV prevailed within the structure of non-Hodgkin lymphomas with primary gastrointestinal involvement, and, thus, negatively impacted the survival and prognosis.

1 December 2022 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
DUDumitrita Urescu
Dumitrita Urescu
VMVasile Musteata
Vasile Musteata
NSNina Sghibneva-Bobeico
Nina Sghibneva-Bobeico
MRMaria Robu
Maria Robu
LMLarisa Musteata
Larisa Musteata
VMVictor Munteanu
Victor Munteanu
Introduction. Non-Hodgkin’s lymphoma is a group of malignant tumors that develop from hematopoietic cells located outside the medullary. They are one of the most common forms of hemoblastosis. Non-Hodgkin lymphoma develops in people of all ages. Morbidity of non-Hodgkin lymphoma increases with age reaching its highest level in people over 50 years of age. Material and methods. A study was carried out through a narrative review of the literature in the form of a synthesis article. The article summarized and systematized various primary studies, dedicated to the epidemiological and diagnostic aspects of aggressive extranodal NHL. Results. Aggressive extranodal NHL remains a major problem, with a fairly large increase in incidence globally. This trend is observed in several countries of the world, thus morbidity increases by 3% annually for women and by 4% for men. Globally, aggressive non-Hodgkin’s lymphoma continues to affect the working-age population. Although patients with primary extranodal NHL tend to report to a medical specialist at a lower stage than those with primary ganglion disease, the number of those addressing in advanced stages continues to be increased. Conclusions. Although diagnosing NHL does not involve great impediments, primary care physicians often detect patients in the late stages of the disease either because of delayed referral to the doctor or because of incorrect diagnosis. Despite the development of new methods of diagnosis and treatment, aggressive extranodal NHL continues to be a current problem of clinical medicine and public health, requiring increased managerial and financial efforts.